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Part of this chapter has been published under the title “Nutrition for children with 
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Essential fatty acids (EFA) cannot be synthesized de novo by humans or animals and 
thus can only be obtained by means of dietary intake. EFA are involved in many 
biological processes; they are essential for normal neurodevelopment and regulation of 
membrane function in several tissues like the brain, retina, liver, kidney, adrenal glands 
and gonads.
1
 In addition, metabolites of EFA are precursors of eicosanoids, which 
strongly modulate processes like platelet aggregation and chemotaxis of the immune 
system.
2
 Accordingly, a shortage of EFA, also known as EFA deficiency, leads to various 
clinical consequences, such as impaired cognitive and motor development, reduced 
growth rate, dry skin, hair loss and functional changes in organs like hearth and liver.
2
 
EFA deficiency is a condition that can develop due to insufficient dietary intake or 
absorption, or due to enhanced metabolism of EFA. This condition is described in detail 
in one of the paragraphs of this chapter. Pediatric patients with cholestatic liver disease 
often encounter EFA deficiency, which is one of the determining factors for failure to 
thrive in these patients. In order to improve the nutritional status of patients with 
Cholestasis-induced failure to thrive (CIFTT), maintenance of intestinal absorptive 
capacity is essential. 
Previous studies on EFA deficiency mainly focused on its effects on the liver, brain and 
heart.
1
 However, little is known about the effects of EFA deficiency on the function and 
physiology of the small intestine. In order to improve the nutritional status of pediatric 
patients, knowledge of (the effects of EFA deficiency on) the small intestinal function is 
essential. Recent studies suggested that EFA deficiency by itself might deteriorate the 
intestinal function, as demonstrated by EFA deficiency induced fat malabsorption.
3
 
Rather than intraluminal effects, intracellular defects in the small intestinal enterocytes 
were suggested to contribute to fat malabsorption during EFA deficiency in mice.
4
  
The aim of this thesis was to characterize the effects of EFA deficiency on the function, 
morphology and (patho)physiology of the small intestine in a murine model. To study the 
intracellular effects of EFA deficiency in more detail, an in vitro model was established.    
Insight into the pathophysiology of EFA deficiency, regarding the small intestinal 
function, might help improve the nutritional status of patients with CIFFT and other 
conditions associated with EFA deficiency.  
 
ESSENTIALS FATTY ACIDS (EFA)  
 
The two EFA, also known as “parental” EFA, are linoleic acid (C18:2ω-6, LA) and α-
linolenic acid (C18:3ω-3, ALA). By means of a cascade of desaturation and elongation of 
the carbon chain, LA and ALA can be converted into their long chain fatty acid 
metabolites (LCPUFA: long chain polyunsaturated fatty acids) of the ω-6 and the ω-3 
families, respectively (Figure 1).
5,6,7
  
Enzymes responsible for desaturation steps are being competed for by different 
LCPUFA. The enzymes have preferred affinity for the ω-3 family of LCPUFA over the ω-
6 family members. The affinity for these two EFA families, on the other hand, is preferred 
over the affinity for non-EFA of ω-9 and ω-7 fatty acids. Desaturation and elongation of 
fatty acids depend on the needs and availability of the LCPUFA in the organism.
8
 LA and 
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ALA are not only converted to LCPUFA; part is used as substrates for β-oxidation, 
representing a source for energy for the organism.
9
 Another relevant function of EFA and 
their LCPUFA metabolites is their role as constituents of the membrane lipids (mainly of 
phospholipids). Within the membrane, they regulate its fluidity, but also the function and 
localization of the proteins within these membranes. EFA and their LCPUFA metabolites 
can also serve as precursors of eicosanoids and leukotrienes which are important 
signaling molecules in inflammation and second messengers of the central nervous 
system. Recently, EFA and LCPUFA (along with other non-essential fatty acids) were 
reported as potent ligands for nuclear receptors, which regulate the gene expression of 




























Figure 1 Essential fatty acids of the ω-3 and ω-6 family, with their source and long chain 
polyunsaturated metabolites (LCPUFA) and enzymes involved in desaturation and elongation of 
EFA and LCPUFA. 
 
Under certain circumstances, for example during excessive intake of dietary LA or during 
low metabolism of LA, LA can be stored in adipose tissue for future use.
11
 Since 
(preterm) infants have limited amounts of adipose tissue and are rapidly growing and 
developing, they are highly dependent on sufficient and continuous intake of dietary 
EFA. 
Within the enterocytes of the small intestine, absorbed EFA and LCPUFA are mainly re-
acylated into triglycerides and subsequently assembled into chylomicrons in order to be 
excreted into the lymph. However, resident EFA are incorporated in membrane 
phospholipids, which are mainly rich in LA and its metabolite arachidonic acid (C20:4ω-
6, AA). The relatively short lifespan of the enterocytes requires a continuous and rapid 
supply of EFA and their metabolites, either from dietary, from biliary or from systemic 
origin. Around 40% of bile consists of EFA- or LCPUFA-acyl chains, making it a very 
important supplier of intestinal EFA.
12




























morphological and dynamic structural changes in the intestinal mucosa. Therefore, the 
intestinal mucosa is highly sensitive and adaptive to dietary changes in EFA.  
As stated above, EFA deficiency in the small intestine can develop in times of low dietary 
intake, enhanced metabolism, and/or malabsorption of (essential) fatty acids. In general, 
severe EFA deficiency can lead to growth retardation, skin lesions, reduced vision, 
impaired cognitive development and steatosis. The symptoms caused by ω-6 fatty acid 
deficiency are more obvious than those caused by ω-3 fatty acid deficiency. 
 
Essential fatty acid (EFA) deficiency  
The supply of EFA in the Western diet is usually sufficient to fulfill the metabolic needs. 
Some chronic intestinal disorders can lead to severe fat malabsorption and thus to EFA 
deficiency. However, most common is the EFA deficiency due to reduced fat absorption 
as a consequence of reduced bile secretion in patients with cholestatic liver diseases or 
reduced activity of pancreatic enzymes, like for example in patients with cystic fibrosis 
(CF).
13,14,15
 EFA deficiency itself aggravates the fat malabsorption in these patients 
leading to even more severe symptoms.
4,3,16
  
Symptoms of EFA deficiency are usually not immediately obvious, especially not for 
isolated ALA deficiency. It is therefore important to have another, preferably biochemical, 
marker to assess EFA deficiency in (pediatric) patients. Plasma measurements of total 
lipid LCPUFA are relatively easy and can function as an indication of EFA status. Yet, 
plasma EFA composition may not correspond to the EFA status of various organs, but 
may rather correlate more closely with recent dietary EFA intake. The EFA composition 
in membrane phospholipids of erythrocytes may be a better indicator of body EFA status, 
based on their relatively long half lives.
17
 This, on the other hand, might only be relevant 
during EFA assessment in severe, long lasting EFA deficiency. Neither plasma nor red 
blood cell phospholipid measurements are likely completely representative for complete 
EFA status, since different tissues are known to have their own specific requirements 
and metabolism of EFA. Unfortunately, it is clinically impossible to determine the EFA 
status in the most relevant tissues, such as for example the central nervous system, and 
therefore plasma or erythrocyte composition of LCPUFA is the most commonly used 
parameter to assess EFA status. For estimation of the severity of combined deficiency of 
ω-3 and ω-6 EFA, the so called triene:tetraene ratio has been introduced by Holman in 
1960.
18
 In case of reduction of both ω-3 and ω-6 EFA, the synthesis of non-essential 
fatty acids of the ω-9 family increases, leading to an enhanced production of the long 
chain metabolite eicosanoic acid (C20:3ω-9, also known as mead acid) from oleic acid 
(C18:1ω-9). The increase of the mead acid is an indicator of LA and ALA deficiency. 
Since sufficient supply of one of the two EFA will prevent an increase in mead acid, this 
ratio can only be used when the concentrations of both EFA are decreased. Although the  
triene:tetraene ratio has been regarded for long as “the biochemical marker of EFA 
deficiency”, it does not provide an overall picture of the EFA and their LCPUFA 
metabolites.
19
 More common is the use of triene:tetraene ratio in combination with other 
determinations of EFA (e.g. plasma profile) in order to obtain a more complete and 
accurate picture of the EFA status in patients. The nature of the disease may influence 
what the best clinically relevant marker is for a certain disease. Magbool et al. have 
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recently demonstrated that in pediatric patients with CF, assessment of serum LA status 
as the clinical indicator of EFA status is more relevant than the triene:tetraene ratio.
19
 
Fatty acid compositions are most often represented as molar percentages, which 
indicate the percentage of an individual fatty acid (or a group of fatty acids) as the 
percentage of total fatty acids in plasma or other compartments. The relative, molar 
percentages are often more relevant than absolute concentrations, since the latter do not 
indicate the changes in membranes, which are mainly influenced by the composition.  
As stated above, a high incidence of EFA deficiency has been reported during 
cholestasis or CF. In both conditions, the small intestinal function seems to be 
affected.
13,14,15,20
 The association of cholestasis and CF in relation to EFA deficiency will 
be discussed in more detail in the next two paragraphs.  
 
Essential fatty acid (EFA) deficiency in cholestasis 
Cholestatic liver diseases (CLD) are characterized by decreased or absent hepatic 
secretion of bile into the intestine, either caused by congenital or acquired diseases.
21,22
 
CLD are associated with several nutritional complications, including EFA deficiency.
23
 In 
general, neonatal and pediatric patients are more affected by CLD than adults. EFA 
deficiency is one of the contributors to “failure to thrive” in pediatric patients with 
cholestasis, known as cholestasis induced failure to thrive (CIFTT). Several treatment 
options aim to reduce the cholestatic symptoms in pediatric patients, as well as their 
negative impact on the nutritional condition. However, CIFFT can be very resistant to 




The most common cause of CLD in children requiring liver transplantation is biliary 
atresia. Biliary atresia is a progressive disorder characterized by an inflammatory 
reaction towards the extrahepatic and intrahepatic bile ducts, leading to destruction and 
subsequent replacement of the normal tissue by fibrotic scar tissue. The etiology of 
biliary atresia remains unknown, although an inflammatory reaction to a detrimental 
stimulus seems to play an initiating role.
26
 Another group of causes for pediatric CLD 
involve Progressive Familial Intrahepatic Cholestasis (PFIC). PFIC constitute a group of 
genetically transmitted disorders, inherited in an autosomal recessive fashion. Three 
phenotypic forms of PFIC have been characterized and attributed to gene defects in 
three different genes (PFIC1-3; official symbols: ATP8B1, ABCB11, ABCB4).
27
  Another 
cause of CLD is non-syndromic paucity of the intrahepatic bile ducts, whose etiology is 
still enigmatic, infections, chromosomal disorders and metabolic disorders have been 
suggested to play a role.
28
 Inborn errors in bile acid synthesis account for another part of 
the children with CLD. Defects have been identified in enzymes catalyzing cholesterol 
catabolism and bile acid synthesis.
28
 CLD in adolescents and young adults is often due 
to autoimmune hepatitis, primary biliary cirrhosis or primary sclerosing cholangitis.
28,29
 
Poor dietary intake is an important factor in the pathophysiological basis of malnutrition 
in children with CLD. The nutritional status may be further compromised by decreased 
absorption of the macronutrients, fat, carbohydrates and proteins. At infant age, fat 
accounts for the most important dietary energy source (up to 50% of total ingested 
energy). It is therefore, not surprising that up to 70% of children with CLD requiring liver 






























Several studies demonstrated the decreased uptake and/or intracellular processing in 
the enterocyte as the main reason for decreased EFA and LCPUFA concentrations 
during EFA deficiency,
3,4
 rather than the decreased activity of desaturases and/or 
elongases as proposed earlier by Socha et al.
14
 In addition, cholestasis has been 
proposed to impair the β-oxidation pathway and can therefore interfere with the last step 
of DHA and DPA metabolism from their precursors.
2,30
 However, in an animal model for 
cholestasis (rats with bile duct ligation), Minich et al. showed no major difference in LA 




Essential fatty acid (EFA) deficiency in cystic fibrosis 
Cystic fibrosis (CF) is still one of the most common genetic disorders among the 
Caucasian population.
20
 It is an autosomal recessive disease caused by a mutation in 
the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The encoded 
CFTR protein mainly functions as a chloride channel.
20
 Over 1500 mutations have been 
identified in the CFTR gene. However, for only a small number of these mutations the 
functional importance has been elucidated. Symptoms of CF are age- and patient-




Gastrointestinal problems include meconium ileus (obstructive condition of the small 
intestine) and pancreatic insufficiency, which both lead to malnutrition and failure to 
thrive.
33,34
 In a sub selection of patients, cirrhosis and cholestatic symptoms may develop 
in CF patients which contribute to an even further detoriation of the nutritional status.
35,36
  
EFA deficiency has been common in CF, particularly in the era that many patients were 
treated with low-fat diets to counteract the steatorrhoea, and was mainly characterized 
by low plasma levels of linoleic acid (C18:2ω-6, LA).
37,38
 Number of events has been 
suggested to contribute to EFA deficiency in CF patients, like pancreatic insufficiency, 
solubilization defects, altered intestinal microclimate and altered enzyme activity of 
desaturases and elongases involved in EFA metabolism. Additionally, increased energy  
expenditure is thought to contribute to the poor nutritional status in CF patients.
39
 
Several attempts to correct for EFA deficiency, with pancreatic enzyme replacement 







The small intestine is one of the largest and most metabolically active tissues. It is 
continuously renewed by processes of proliferation and differentiation, leading to a highly 
ordered tissue architecture.
44
 Enterocytes are responsible for the absorption of dietary 
and endogenous compounds. Enterocyte differentiation can be studied by assessment of 
the expression of brush border enzymes, such as lactase and sucrase-isomaltase. The 
three transcription factors Gata-4, Hnf1α and Cdx2 regulate the expression of the 
corresponding genes.
45
 Cdx2 also plays an essential role in the organogenesis of the 
midgut into the small intestine.
46
 Enterocytes located within different regions of the small 
intestine (duodenum, jejunum and ileum) vary in their functional capacities; while for 
example the carbohydrate absorption mainly takes place in the more proximal part, bile 
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salt uptake occurs mainly in the terminal ileum. Small intestinal morphology is 
characterized by two distinct axes, the horizontal axis, i.e. the proximal to distal (or 
anterior to posterior) small intestine, and the vertical axis, representing the crypt-to-villus 




Crypts and villi  
Already during the formation of the primitive gut at gestational age of 9 weeks in 
humans, the morphogenesis of nascent villi and crypts occurs within the epithelium 
(Figure 2). At this point, cellular proliferation is concentrated mainly within the intervillus 
region. During development, the intervillus regions are transformed into crypts by means 















Figure 2 Histological staining of mouse small intestine indicating the crypt and villus regions. Crypts 
are located at the bottom and contain stem cells which migrate towards the upper located villus 
region. Fully differentiated cells represent mainly the absorptive cells, the enterocytes.  
It has been accepted that the small intestinal epithelium is maintained by a population of 
tissue-specific stem cells.
48
 Developed crypts contain a small, proliferating group of stem 
cells which give rise to different intestinal cell types, subsequently migrating towards the 
adjacent villi.
48,49
 In most mammals, re-differentiation of the intestine starts after birth, 
simultaneous with increased proliferation. Increased proliferation eventually leads to 
development of larger crypt depth and increased villus height. Parallel with the 
development of the crypt and villi, different cell lineages develop from the immature cells, 
including absorptive cells (enterocytes), mucus secreting cells (goblet cells), various 
enteroendocriene cells and enzyme- and antibacterial peptides secreting cells (Paneth 
cells).
48,50,51,52
 All the epithelial cells, originate from the same multipotent stem cells that 
proliferate from the bottom of the crypt. Enterocytes account for almost 90% of all 
epithelial cells within the small intestine. Research described in this thesis focuses on the 
enterocytes, the most relevant intestinal cell type with regard to absorption and 
metabolism of dietary compounds.  
Apical and basolateral compartment in the enterocyte  
Enterocytes are absorptive intestinal cells characterized by two domains within the cell, 
Villus region  
(differentiating cells) 




























namely the apical and the basolateral domain,
53
 separated by the tight junctions.
54
 It is 
the existence of these domains that plays an important role in the maintenance of the 
intestinal barrier function. One of the most remarkable features of the absorptive 
enterocytes is the presence of the so called brush border membrane (BBM) at the apical 
site of the cell which consists of many closely packed microvilli.
53
 Apical and basolateral 
domains differ in their expression of different enzymes and transporters.
55
 The 
histocompatibility antigens are specifically located at the basolateral membrane of the 
enterocyte.
56
 Enzymes (hydrolases) appear only within the BBM at the end of the 
physiological differentiation process of the enterocyte, i.e. when the proliferating cells 
reach the villi during their migration from the crypts. For this reason, many hydrolytic 
enzymes, like lactase and sucrase isomaltase, are used as the markers for the 
differentiation status of the absorptive enterocytes.
57
 The exact pathways by which 
enterocytes deliver different newly synthesized proteins from the Golgi apparatus to the 
apical or basolateral site are still the subject of intense cell biological research.  
 
Enterocyte function 
Small intestine is one of the first barriers to be encountered by nutrients after their dietary 
ingestion. Absorption of most important dietary and hepatobiliary compounds is 
described below. Figure 3 shows a short schematic summary of enzymes and proteins 
involved in processes of absorption and metabolism of the small intestine. 
 
Fat absorption 
Dietary fat is mainly absorbed as triglycerides in the human diet and in smaller amounts 
as phospholipids (~10%).
58
 Intestinal absorption of fat can be separated in intraluminal 
and intracellular events, and these have been reviewed extensively.
58,59,60,61
 Intraluminal 
steps of fat absorption can be divided into emulsification, lipolysis, and solubilization, 
followed by translocation across the epithelial apical membrane. Emulsification involves 
mechanical disruption and partial hydrolysis of triglycerides within the stomach and 
results in increasing the oil-water surface area by decreasing the median size of the fat 
droplets from the diets. This process is stimulated mechanically by shear force in the 
stomach and the pylorus and biochemically by generating the lipolytic products of 
triglycerides, namely diacylglycerol and free fatty acids. 
The emulsified dietary fat subsequently enters the first part of the small intestine, the 
duodenum, where it is subjected to lipolysis by pancreatic lipases into monoacylglycerlol 
and free fatty acids. Triglyceride lipolysis by pancreatic lipases requires a co-factor, 
pancreatic co-lipase, which is able to facilitate proper binding of the lipase to the oil-
water surface of the fat emulsion. The secretion of the pancreatic lipase into the 
duodenum is often associated with gallbladder contraction and cholecystokinin release. 
Digestion of phospholipids derived from diet and bile, occurs within the duodenum by the 
enzyme phospholipase A2. However, as demonstrated by studies in PLA2-deficient mice, 
additional enzyme(s) can compensate for pancreatic PLA2 in catalyzing phospholipid 
digestion.
62
 Hydrolysis of phospholipids results in production of lyso-phospholipids and 
free fatty acids, which can subsequently be translocated across the enterocyte apical 
membrane. Lipolytic products must be solubilized in order to be soluble and thus 
transportable in the aqueous phase of the intestinal lumen and across the so called 
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unstirred water layer, which is the border between the luminal site of the intestine and 
the BBM of the enterocytes. Solubilization of the lipolytic products is performed by biliary 
bile salts and phospholipids by means of their mixed micellar formation with the products 
of lipolysis.
63
 Mixed micellar solubilization increases the solubility of the lipolytic products 
up to 1000-fold.
64
 Compared to diglycerides and fatty acids, phospholipids are more 
independent of bile salts for the mucosal uptake, since they can interact more easily with 


































Figure 3 Major small intestinal enzymes, proteins and nuclear receptors involved in fatty acid, 
carbohydrate, cholesterol and bile salt absorption and metabolism. On the left, the apical site with 
the brush border membrane and on the right the basolateral site of the enterocyte is indicated. 
ABCA1, Abc-transporter a1; ABCG5/8, Abc-transporter g5/g8; ACAT2, Acyl-coenzyme 
A:cholesterol Acyltransferase 2; ASBT, Apical sodium dependent bile acid transporter; DGAT1/2, 
Acyl coenzyme A:diacylglycerol acyltransferase 1/2; FABP, Fatty acid bindind protein; FAT, Fatty 
acid transporter; FATP4,fatty acid transport protein; FGF15, Fibroblast growth factor 15; FGFR4, 
Fibroblast growth factor receptor 4; FXR, Farnesoid X receptor, GLUT2/5, Glucose transporters 2/5; 
IBABP, Ileal bile acid binding protein; LDLR,  Low density lipoprotein receptor; LXR, Liver X 
receptor; MGAT, monoacylglycerol O-acyltransferase 1; MTTP, microsomal triglyceride transfer 
protein; NPC1L1, Niemann-Pick C1 like 1; OSTα/ß, Heteromeric organic solute transporter alpha-
beta; PPAR, Peroxisome proliferator-activated receptors; RXR, Retinoid X receptor; SI, Sucrase 
isomaltase; SGLT, Sodium glucose cotransporter; SHP, short heterodimer partner; SRBI, 
scavenger receptor BI. 
 
After lipolysis and solubilization, fatty acids dissociate from different lipid classes 






























 Translocation of the free fatty acids and across the BBM subsequently 
occurs. Whether this translocation occurs only via passive diffusion, or in addition via fat 
transporters in the enterocytes, remains unclear. Several candidate transporters have 
been identified to facilitate fat transport across the BBM of the enterocyte, including the 
fatty acid transport protein 4 (FATP4; official symbol SLC27A4) and the fatty acid 
translocase (FAT; official symbol CD36), both located at the BBM of the 
enterocytes.
66,67,68
 However, FATP4 has been shown to localize within the enterocyte as 
well and thus not exclusively at the BBM.
69
 More importantly, several studies in mice with 
deletions in these transporters clearly have indicated that these transporters are not 
essential. Rather, they might co-facilitate in dietary fatty acid absorption or influence their 
intracellular processing, as these mice do not show severe signs of fat 
malabsorption.
70,71
 Within the enterocyte re-esterification and chylomicron formation 
occur, starting with the binding of fatty acids to the intestinal fatty acid binding protein 
(IFABP; official symbol FABP2) or liver fatty acid binding protein (LFABP; official symbol 
FABP1) which escort them to the endoplasmatic reticulum.
72
 Interestingly, I-FABP 
deficiency in mice does not lead to fat malabsorption, indicating that I-FABP is not 
essential for sufficient absorption of dietary fat.  
Within the smooth endoplasmatic reticulum absorbed fatty acids are acylated into 
triglycerides via two different pathways. Under physiological conditions, the so called 
monoacylglycerol pathway is the predominant one in which 1 acetylated fatty acid 
molecule and 2 molecules of monoacylglycerol are re-esterificated into triglycerides. The 
enzymes involved in the two steps of monoacylglycerol pathway are acyl-
CoA:monoacylglycerol acyltransferases (MGATs). These enzymes convert 
monoacylglycerol and fatty acyl-CoA into diacylglycerol. Acyl-CoA: diacylglycerol 
acyltransferases (DGATs), on the other hand, convert diacylglycerol intro triglycerides. 
The second, physiologically less prominent route is the α-glycerophosphate pathway, 
which becomes of major importance under conditions of fat malabsorption. In the first 
two steps, glycerol-3-phosphate is converted into phosphatidic acid by means of 
glycerol-3-phosphate acyltransferases and 1-acylglycerol-3-phosphate O-
acyltransferases. Subsequently, phosphatidic acid is converted to diacylglycerol by PA 
phosphatases. Diacylglycerol produced by this pathway is preferentially used to 
synthesize new phospholipids. The rest of the diacylglycerol is used to produce 
triglycerides, which are thought to be slightly different from triglycerides produced by the 
monoacylglycerol pathway, since the triglycerides from the latter pathway are 
transported faster across the basolateral membrane of the enterocytes. 
The last step of lipid absorption involves the assembly of newly produced triglycerides, 
phospholipids, cholesterol, cholesteryl esters and apolipoproteins (mainly apoB48) into 
pre-chylomicrons.
73
 This process requires the microsomal triglyceride transfer protein 
(MTTP) within the smooth endoplasmatic reticulum. Afterwards, these pre-chylomicrons 
are transported towards the Golgi apparatus, where they transform into mature 
chylomicrons, These are eventually released in the cytoplasm and exocytosed into the 
interstitium, ending up in lymphe. 
 
Peroxisome proliferator-activated transcription factors (PPARs)  
Recently, fatty acids have been identified as the natural ligands for peroxisome 
CHAPTER 1 
20 
proliferator-activated transcription factors (PPARs) α, β/δ and γ which, like the other 
nuclear receptors, heterodimerizes with retinoid X receptor (RXR)
74
. Although the 
functions of PPARs have been studied extensively in the liver, their role in the intestine is 
still emerging. PPARα activation in the intestine has recently been demonstrated to 
activate the transcription of several genes involved in fatty acid, triacylglycerol, sterol and 
bile acid metabolism.
75
 PPARδ activation, on the other hand, was recently shown to 
reduce intestinal cholesterol absorption efficiency. 
76
 PPARγ within the intestine has 
recently been implied in modulating epithelial and mucosal inflammation.  
 
Carbohydrate absorption  
Carbohydrates in diet are derived from starch (polysaccharides, 75%) or sugars (di- and 
monosaccharides). Starch is composed of amylase and amylopectin, and is digested by 
salivary and pancreatic amylases. Afterwards, final hydrolysis to glucose at the brush 
border of the enterocytes in the proximal part of the small intestine occurs by sucrase-
isomaltase and maltaseglycoamylase. Glucose can subsequently be taken up by the 
sodium-dependent glucose transporter (SGLT1; official symbol SLC5A1).
55
 Lactose and 
sucrose are the quantitatively most important dietary disaccharides. They are hydrolyzed 
into glucose and galactose or fructose, respectively. Hydrolysis of lactose and sucrose is 
catalyzed by the enzymes lactase and sucrase isomaltase, respectively, anchored within 
the brush border of the enterocytes. Monosaccharides are transported directly across the 
BBM by means of SGLT1 (glucose and galactose) or GLUT5 (fructose; official symbol 
SLC2A5), without requiring hydrolysis.
77
 Subsequently, basolateral transport of all 
carbohydrates occurs via the universal GLUT2 (official symbol SLC2A2) transporter.
77,78
  
Studies in rats with bile duct ligation demonstrated that cholestasis is not associated with 
severely affected absorption and digestion of carbohydrates.
79,80
 However, whether EFA 
deficiency affects digestion and absorption of dietary carbohydrates is not known. 
 
Cholesterol absorption 
Between 25% and 85% of dietary cholesterol is absorbed from the small intestine in 
humans.
81,82
 Once in the lumen of proximal small intestine, cholesterol and plant sterols 
are most likely transported into the enterocyte by means of the recently identified, apical 
transporter Niemann-Pick C1-like 1 protein (NPC1l1).
81
 The function of this protein can 
be illustrated by the phenotype of mice lacking NPC1l1 protein, showing severely 
reduced cholesterol absorption compared to their wild type littermates.
81
 Within the 
enterocytes, cholesterol is esterified into cholesteryl esters by means of the acyl-
coenzyme A:cholesterol acyltransferase 2 (ACAT2), which has a high affinity for 
cholesterol, but not for plant sterols.
83
 This results in packaging of the cholesteryl esters 
into chylomicrons, which are subsequently secreted into the circulation. Recent studies 
demonstrated that a fraction of the enterocytic cholesterol can be secreted into the 
circulation independent from the chylomicron pathway. Direct secretion across the 
basolateral membrane occurs in monomeric form, to be subsequently incorporated into 
the HDL particles.
84
 This basolateral transport occurs via the ATP binding cassette 
transporter 1 (ABCA1).
84
  Scavenger receptor class B, member 1 (SR-BI; official symbol 
SCARB1) and LDL receptor (LDLR), localized at the basolateral site of the enterocyte, 






























 Unesterified plant sterols are not assembled for basolateral secretion, but 
are transported back to the intestinal lumen along with unesterified cholesterol. This 
apical transport of plant sterols and unesterified cholesterol from the enterocyte into the 
lumen is facilitated by an ABC heterodimeric transporter ABCG5/ABCG8.
86
 Within the 
enterocyte, the nuclear liver X receptor (LXRα and LXRβ; official symbols NR1H3 and 
NR1H2) is expressed, which tightly regulates cholesterol and fatty acid metabolism by 
inducing the transcription of genes involved in these metabolic pathways (ABC 
transporters, SREBP1c and SREBP2; official symbols SREBF1 and SREBF2).
87
 
Until recently, hepatobiliary secretion of cholesterol has been thought as the most 
prominent way of cholesterol excretion from the body. This is rather peculiar, since 
already in 1927 an alternative pathway has been proposed, involving direct secretion 
from the intestine. However, this latter pathway has never been validated or paid 
sufficient scientific attention. Recently, the alternative pathway has become re-
appreciated, since in various conditions and models the fecal excretion of neutral sterols 
was higher than the sum of dietary and biliary cholesterol entering the intestinal 
lumen.
88,89
 Direct transintestinal pathway for cholesterol excretion (TICE) has been 
demonstrated in mice by van der Velde et al.
90
 The capacity of the intestinal cholesterol 
excretion pathway was exactly sufficient to account for the missing cholesterol and twice 
as high as the quantitative hepatobiliary secretion. This observation indicated the 
relevance of TICE in excretion of cholesterol in mice.
90
 Importance of TICE in other 
species has not been studied in detail so far. TICE was demonstrated to depend on the 
dietary fat content.
91
 The EFA deficiency might, therefore, be associated with alterations 
in TICE. However, the effects of EFA deficiency on cholesterol metabolism in the 
intestine have not been studied so far. 
 
Small intestine and the enterohepatic circulation of bile salts 
Bile salts are synthesized in the liver from cholesterol via the neutral or the acidic 
pathway.
92
 Under physiological conditions, bile salts are subsequently secreted via bile 
into the intestine. Within the intestine the bile salts are almost completely reabsorbed; 
only around 5% of the endogenous bile salts escape the reabsorption and is excreted via 
the feces every day. Unconjugated bile salts in the small intestine and in colon can be 
transported passively.
93,94
 However, conjugated bile salts require facilitated transport 
across the BBM. This is achieved by means of the apical sodium-dependent bile salt 
transporter (ASBT/ISBT; official symbol SLC10A2), mainly expressed in the terminal 
ileum. The intracellular transport of bile acids from the apical to the basolateral 
compartment was thought to be facilitated by the ileal bile acid binding protein (IBABP; 
official symbol FABP6);
95,96
  however, the exact role of IBABP in the intracellular 
trafficking of bile salts is still under debate.
97
 Within the cell, bile salts can bind to and 
activate the nuclear hormone farnesoid receptor (FXR; official symbol NR1H4), which is 
an important regulator of bile salt homeostasis.
98,99
 Activated FXR initiates the 
transcription of a whole cascade of genes important for bile salt metabolism. One of 
these genes is the small heterodimer partner (SHP; official symbol NR0B2), which leads 
to subsequent ASBT repression.
100,101
 Another intestinal protein which is tightly regulated 
by the activated FXR is the fibroblast growth factor 19 (FGF19, mouse homologue is 
Fgf15).
102
 Upon FXR activation, FGF19 is released into the circulation, in order to be 
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transported to the liver.
102,103
 In the liver, FGF19 binds to the fibroblast growth factor 
receptor 4 (FGFR4) on the hepatocyte cell membrane. This binding leads to the 
activation of the JNK pathway and repression of cholesterol 7-α-hydroxylase (CYP7A1) 
and sterol 12-α-hydroxylase (CYP8B1), resulting in decreased bile salt synthesis.
102,103
 
Recent studies demonstrated that in addition to intestinal/hepatic FGF19/FGFR4 
signaling pathway, liver FGFR4/FGF19 pathway might exist to protect the liver under 
conditions of bile salt accumulation.
103,104
 Another study reported expression of FGFR4 
at the basolateral site of the enterocytes and in cholangiocytes, suggesting the existence 
of a feedback loop mechanism of FGF19/FGFR4 within the intestine and bile ducts. 
Excretion of bile salts in the enterocytes occurs via basolaterally localized heterodimeric 




Manifestation of the impaired small intestinal function in common intestinal 
disorders 
Two common small intestinal disorders with a profound impact at pediatric age are celiac 
disease and Crohn’s disease. Both conditions can severely affect small intestinal 
morphology and function, and lead to malabsorption to nutrients and to growth failure. 
Celiac disease is a form of autoimmune disease of the small intestine leading to nutrient 
malabsorption and immune reaction to transglutaminidase in genetically predisposed 
subjects. It is a life-long condition characterized by villous atrophy (blunted villi), 
enhanced cell proliferation, increased number of crypts and increased infiltration of 
lymphocytes upon ingestion of gluten. Symptoms vary largely among the patients and 
disappear upon a gluten-free diet.
107
 Crohn’s disease is anti-inflammatory disease which 
can affect the whole gastrointestinal tract. Within the small intestine neutrophil infiltration 
into the epithelium can occur along with atypical crypt branching and finally with villous 
blunting.
108
 Intestinal permeability might also be profoundly increased, associated with 
an impaired barrier function.
109
 Together, these pathophysiological factors can lead to 
malabsorption of nutrients and growth failure. The exact factors involved in 
pathophysiology of EFA deficiency in the small intestine which lead to nutrient absorption 
remain unclear. Therefore, it is useful to study how EFA deficiency affects the small 
intestinal function and morphology.  
 
AIM AND THE OUTLINE OF THE THESIS 
 
Clinical conditions associated with EFA deficiency are accompanied by impaired 
nutritional status. In children with cholestasis, EFA deficiency aggravates the cholestasis 
induced failure to thrive (CIFTT). In animal models, EFA deficiency by itself is associated 
with malabsorption of fat, even in absence of cholestasis or CF. Previous studies 
suggested that defects in the small intestine during EFA deficiency were located at the 
intracellular level. We aimed to characterize and unravel the effects of EFA 
deficiency on the pathophysiology and the function of the small intestine. 
First, we studied the epithelial histology and function by analyzing the morphology and 
nutrient absorption of the small intestine during EFA deficiency (chapter 2). We describe 
the effects of EFA deficiency in mice on the absorption of carbohydrates and on the 




























administration of stably labeled glucose and lactose, we determined the absorption and 
digestion of these compounds in vivo. In chapter 3 we further characterized the effects 
of EFA deficiency on intestinal physiology by determining the jejunal cholesterol 
absorption and metabolism during EFA deficiency. The results obtained are based on 
the physiological parameters and the microarray analysis of mouse jejunal tissue.  
In chapter 4 we determined the effects of EFA deficiency on the enterohepatic 
circulation (EHC) of bile salts. Bile salt (re)absorption is a small intestinal function which 
does not depend on the jejunal intestinal epithelium, but rather on that of the terminal 
ileum. In order to study whether EFA deficiency differentially affects different small 
intestinal segments, we studied the EHC in EFA-deficient mice. Small intestine plays an 
important role in the EHC of bile salts by regulating the feedback mechanism of the 
hepatic bile salt synthesis. Previous studies in EFA-deficient mice revealed elevated bile 
salt secretion and bile flow. The underlying mechanism of this finding remained unclear. 
We determined several parameters of the enterohepatic circulation of bile salts using the 
stable isotope dilution technique, combined with bile duct cannulation. Small intestinal 
regulatory mechanisms of the enterohepatic circulation were assessed by analyzing the 
expression of the intestinal genes implicated in bile salt metabolism.  
In order to study in more detail the intracellular effects of EFA deficiency on the small 
intestine, an in vitro model of EFA deficiency has been established. Differentiating Caco-
2 cells cultured in EFA-deficient or control medium were characterized and validated as 
a model for EFA deficiency (chapter 5). We described the effects of EFA deficiency on 
cell differentiation, gene expression and morphology, based on several in vitro 
experiments in EFA-deficient Caco-2 cells.  
To optimize nutritional condition during cholestatic liver disease, one could aim to 
decrease the fat malabsorption by administration of exogenous absorption enhancers. 
Chapter 6 describes experiments in two different rat models of fat malabsorption; one 
with impaired lipolysis (pancreatic insufficiency model) and one with reduced 
solubilization (cholestatic model). In these rat models we studied the effects of the 
compound Gelucire
®
44/14 on fat malabsorption in vivo. Gelucire
®
44/14 is currently used 
to improve the absorption of poorly soluble drugs. Fat absorption was assessed in both 




Chapter 7 provides a summary of the most relevant findings in this thesis and future 
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